HIV Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune checkpoint inhibitors in infectious disease.
Inflammatory and Immune Mechanisms for Atherosclerotic Cardiovascular Disease in HIV.
From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy.
Cardiac and Renal Comorbidities in Aging People Living With HIV.
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.
The role of TEMRA cell-mediated immune senescence in the development and treatment of HIV disease.
The immune response to SARS-CoV-2 in people with HIV.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 regulatory approval from EMA on record.
- 2 clinical trials expected to report results, the earliest in Q3 2026.
- Active recent publication activity.
- Q3 2026A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)
- Q1 2029A Phase IIIB, Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition
Research HighlightsViewHide
- 2025-10-20Kaposi's Sarcoma: A Non-Communicable Outcome Mainly Prompted by Communicable Diseases in Sub-Saharan Africa.Mamimandjiami AI · 2025
Clinical MilestonesViewHide
- 2026-06-17A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)Results posted
- 2026-03-19A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
- 2025-08-22A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
- 2026-05-27A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)Results expected Q3 2026
- 2025-12-22A Phase IIIB, Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV AcquisitionResults expected Q1 2029
Regulatory UpdatesViewHide
- 2026-04-27Approval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
- 2026-06-17ClinicalA Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)Results posted
- 2026-05-27ClinicalA Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)Results expected Q3 2026
- 2026-04-27RegulatoryApproval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
- 2026-03-19ClinicalA Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
- 2025-12-22ClinicalA Phase IIIB, Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV AcquisitionResults expected Q1 2029
- 2025-10-20ResearchKaposi's Sarcoma: A Non-Communicable Outcome Mainly Prompted by Communicable Diseases in Sub-Saharan Africa.Mamimandjiami AI · 2025
- 2025-08-22ClinicalA Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syn… (2026)
Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)
Approval — Tecovirimat SIGA is indicated for the treatment of the following viral infections in adul… (2022)
Approval — Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM)… (2020)
Approval — Tygecycline Accord is indicated in adults and in children from the age of eight years for… (2020)
Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)
Approval — Posaconazole Accord is indicated for use in the treatment of the following fungal infecti… (2019)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- HIV Infections22
- COVID-194
- HIV-13
- Extracellular Vesicles2
- Immune Checkpoint Inhibitors2
- Neoplasms2
- Acquired Immunodeficiency Syndrome1
- Aging1
Leading journals6
- International journal of molecular sciences3
- Circulation research2
- Frontiers in immunology2
- Immunological reviews2
- Microbiome2
- Molecular neurobiology2
Leading researchers8
- Clifford DB2
- Ellis RJ2
- Gelman BB2
- Letendre SL2
- Lewin SR2
- Marra CM2
- Abbar B1
- Abramson I1
Affiliations (unnormalised)6
- University of California San Diego3
- London School of Hygiene and Tropical Medicine2
- School of Medicine2
- University of Cape Town2
- Washington University in St. Louis2
- "L. Spallanzani" National Institute for Infectious Diseases (INMI)1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
HIV infections comprise a spectrum of disease caused by human immunodeficiency virus, ranging from asymptomatic seropositivity through AIDS-related complex to acquired immunodeficiency syndrome (AIDS). The literature grounding emphasizes the infection’s chronic course, its immunologic consequences, and its complications, mortality, microbiology, virology, and epidemiology.
The grounding supports human immunodeficiency virus as the cause of the infection. It also links transmission-related context to sexual behavior and male homosexuality in the literature, but does not provide a fuller etiologic breakdown beyond HIV infection itself.
HIV infection is characterized by persistent viral infection with host-pathogen interactions that drive immune dysfunction. The supplied reviews highlight chronic antigen exposure leading to T-cell exhaustion, maintenance of latently infected reservoirs, and dysregulation of cytokines and chemokines that can contribute to inflammatory injury. Microglial cells are described as a major latent HIV-1 reservoir in the brain, linking infection to central nervous system involvement and HIV-associated neurocognitive disease.
The grounding indicates that sexual behavior, including male homosexuality, is a studied epidemiologic context for HIV infection. It also suggests that exposure to sexually transmitted infections is relevant in HIV prevention settings, but it does not support a broader list of risk factors.
The supplied material supports antiretroviral therapy, including combination antiretroviral therapy, as the core treatment modality for HIV infection. It also mentions HIV preexposure prophylaxis in prevention-focused literature, but does not provide treatment regimens or other specific drug classes beyond antiretroviral therapy.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.